Degarelix
Top View
- Degarelix for Treating Advanced Hormone-Dependent Prostate Cancer
- FIRMAGON® (Degarelix for Injection)
- Company Corporate Presentation
- Gonadotropin Releasing Hormone Analogs (Gnrh)
- Gnrh Antagonists Have Direct Inhibitory Effects on Castration-Resistant Prostate Cancer Via Intracrine Androgen and AR-V7 Expression Vito Cucchiara1, Joy C
- Relugolix (Orgovyx™) EOCCO POLICY
- Luteinizing Hormone-Releasing Hormone Antagonists
- WO 2015/052204 Al Llll II II 11III II
- Management of Infertility Appendixes
- Degarelix (Firmagon®) Vs Leuprolide (Lupron Depot®) in Patients with Advanced Prostate Cancer: Further Analysis from a Phase Iii Pivotal Trial
- Degarelix for Injection Label
- FIRMAGON® Fact Sheet Degarelix
- An Update on the Use of Degarelix in the Treatment of Advanced Hormone-Dependent Prostate Cancer
- Advances in Therapeutic Peptides Targeting G Protein-Coupled Receptors
- Phase 3 HERO Study Design: Evaluation of the Safety and Efficacy of Relugolix, a Novel Oral Gnrh Receptor Antagonist, in Men with Advanced Prostate Cancer
- Effect of Gonadotropin-Releasing Hormone Antagonist on Risk of Committing Child Sexual Abuse in Men with Pedophilic Disorder a Randomized Clinical Trial
- Gnrh Antagonist Treatment of Malignant Adrenocortical Tumors
- 214621Orig1s000